Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles

Idrissa Diallo; Abderrahim Benmoussa; Jonathan Laugier; Abdimajid Osman; Walter E Hitzler; Patrick Provost

doi:10.3389/fcvm.2020.00031

Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles

Front Cardiovasc Med. 2020 Mar 19:7:31. doi: 10.3389/fcvm.2020.00031. eCollection 2020.

Authors

Idrissa Diallo^{1

2}, Abderrahim Benmoussa^{1

2}, Jonathan Laugier^{1

2}, Abdimajid Osman^{3

4}, Walter E Hitzler⁵, Patrick Provost^{1

2}

Affiliations

¹ Research Center of the CHU de Québec, Quebec, QC, Canada.
² Department of Microbiology-Infectious Disease and Immunity, Faculty of Medicine, Université Laval, Quebec, QC, Canada.
³ Department of Clinical Chemistry, Linköping University, Linköping, Sweden.
⁴ Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
⁵ Transfusion Center, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

Abstract

Despite improvements in donor screening and increasing efforts to avoid contamination and the spread of pathogens in clinical platelet concentrates (PCs), the risks of transfusion-transmitted infections remain important. Relying on an ultraviolet photo activation system, pathogen reduction technologies (PRTs), such as Intercept and Mirasol, utilize amotosalen, and riboflavin (vitamin B2), respectively, to mediate inactivation of pathogen nucleic acids. Although they are expected to increase the safety and prolong the shelf life of clinical PCs, these PRTs might affect the quality and function of platelets, as recently reported. Upon activation, platelets release microparticles (MPs), which are involved in intercellular communications and regulation of gene expression, thereby mediating critical cellular functions. Here, we have used small RNA sequencing (RNA-Seq) to document the effect of PRT treatment on the microRNA profiles of platelets and derived MPs. PRT treatment did not affect the microRNA profile of platelets. However, we observed a specific loading of certain microRNAs into platelet MPs, which was impaired by treatment with Intercept or its Additive solution (SSP+). Whereas, Intercept had an impact on the microRNA profile of platelet-derived MPs, Mirasol did not impact the microRNA profile of platelets and derived MPs, compared to non-treated control. Considering that platelet MPs are able to transfer their microRNA content to recipient cells, and that this content may exert biological activities, those findings suggest that PRT treatment of clinical PCs may modify the bioactivity of the platelets and MPs to be transfused and argue for further investigations into PRT-induced changes in clinical PC content and function.

Keywords: clinical platelet concentrate; extracellular vesicles; intercept; microRNA; mirasol; pathogen reduction; small RNA-sequencing.